摘要:
The present invention relates to pyridopyrimidine derivatives according to formula (I) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.
摘要:
The present invention relates to novel pyrazolopyridinone derivatives according to formula (I) and a process of manufacturing thereof. These pyrazolopyridinone derivatives can be used as LPA receptor antagonists for the treatment of various herein disclosed diseases.
摘要:
Compounds of the formula (I), in which W, R, R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumors.
摘要:
The invention relates to a process for the manufacture of enantiomerically enriched or pure compounds of formula I wherein R1, R2, R3, R6, R7 and Q are defined as in claim 1 as well as their crystalline forms for the treatment of proliferative diseases such as cancer.
摘要:
Disclosed are compounds of formula (I), which are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and which can be employed, inter alia, for the treatment of tumours.
摘要:
Compounds of the formula (I), in which R1, D, E, L, Q, X and q have the meanings indicated in Claim 1, can and be employed for the treatment of tumours.
摘要:
Compounds of the formula (I), in which R, R1, R2, R3, R4, R5, R6, R7, R8, Z1, Z2, Z3, k and Y1 have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.
摘要翻译:式(I)化合物,其中R 1,R 2,R 2,R 3,R 4, R 5,R 6,R 7,R 8,Z 1,..., Z 2,Z 3,Z和Y 1具有权利要求1中所示的含义,特别可以用于 治疗肿瘤。
摘要:
Disclosed are compounds of formula (I), wherein W, R, R1, R2, R3, R4, R5, R6, and R7 have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.
摘要:
Compounds of the formula (I) in which W, R1, R2, R3, R4, and q have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours.